Empagliflozin reduces myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: A hyperpolarized ¹³ C magnetic resonance spectroscopy study.

ABSTRACT:

Aim

To investigate the effects of the sodium-glucose co-transporter-2 inhibitor empagliflozin on myocardial ketone body utilization in diabetic, obese rats with spontaneously hypertensive heart failure (SHHF), after 6 months of treatment.

Materials and methods

Myocardial ketone body utilization was measured in vivo real time using a novel ketone probe (hyperpolarized [3-¹³ C]acetoacetate) and magnetic resonance spectroscopy (MRS). Myocardial glucose utilization and cardiac function were also determined in vivo using hyperpolarized [1-¹³ C]pyruvate MRS and magnetic resonance imaging (MRI), respectively. Myocardial fatty acid uptake and liver ketogenesis were assessed via protein expression.

Results

At baseline, myocardial ketone and glucose utiliz

SUBMITTER: Abdurrachim D 

PROVIDER: S-EPMC6587455 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature